AZNAstraZenecaSigning up patients
A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
Mantle-cell Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 55 (planned)
- Started
- Sep 5, 2025
- Main results expected
- Dec 31, 2027
- Fully finished
- Jun 30, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Best Overall Response Rate (ORR)
Measured over: From acalabrutinib start to approximately 1 year thereafter
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07029737 · record last updated 2026-10-27 · checked 2026-11-09 15:47 UTC